Serum Anti-Müllerian Hormone in the Diagnosis of Polycystic Ovary Syndrome in Association with Clinical Symptoms
Polycystic ovary syndrome (PCOS) is one of the most prevalent endocrine diseases affecting women of reproductive age. The pathogeny of PCOS is still not completely understood, but one contributing factor that has been proposed is anti-Müllerian hormone (AMH). There is currently no clear cor...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-10-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/9/4/136 |
| _version_ | 1818039340801982464 |
|---|---|
| author | Nada Ahmed Asma A. Batarfi Osama S. Bajouh Sherin Bakhashab |
| author_facet | Nada Ahmed Asma A. Batarfi Osama S. Bajouh Sherin Bakhashab |
| author_sort | Nada Ahmed |
| collection | DOAJ |
| description | Polycystic ovary syndrome (PCOS) is one of the most prevalent endocrine diseases affecting women of reproductive age. The pathogeny of PCOS is still not completely understood, but one contributing factor that has been proposed is anti-Müllerian hormone (AMH). There is currently no clear correlation between levels of AMH and incidence of PCOS in Saudi Arabian patients. The goal of this study was to determine the threshold of AMH and correlate it with PCOS clinical features to facilitate a proper diagnosis for PCOS. In this case-control study, we recruited 79 PCOS women and 69 normal ovulatory women; PCOS patients were diagnosed according to the Rotterdam criterion. On days 2−4 of the menstrual cycle, transvaginal/abdominal ultrasound was performed and serum levels of AMH, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) were measured for all participants. The receiver operating characteristic curve (ROC) was used to determine the AMH diagnostic cut-off at 3.19 ng/mL, with 72% sensitivity and 70% specificity; AMH > 3.19 ng/mL was significantly correlated with PCOS. High AMH levels were correlated with age at menarche, polycystic ovarian morphology (PCOM), and oligo/amenorrhea. Serum AMH is a promising diagnostic marker of ovarian dysfunction in PCOS patients especially in cases in which the evaluation of PCOM was complicated. |
| first_indexed | 2024-12-10T07:57:05Z |
| format | Article |
| id | doaj.art-28fbdcd44b0f4d03aa9256420f54bbfd |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-12-10T07:57:05Z |
| publishDate | 2019-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-28fbdcd44b0f4d03aa9256420f54bbfd2022-12-22T01:56:53ZengMDPI AGDiagnostics2075-44182019-10-019413610.3390/diagnostics9040136diagnostics9040136Serum Anti-Müllerian Hormone in the Diagnosis of Polycystic Ovary Syndrome in Association with Clinical SymptomsNada Ahmed0Asma A. Batarfi1Osama S. Bajouh2Sherin Bakhashab3Biochemistry Department, King Abdulaziz University, P.O. Box 80218, Jeddah 21589, Saudi ArabiaBiochemistry Department, King Abdulaziz University, P.O. Box 80218, Jeddah 21589, Saudi ArabiaDepartment of Obstetrics and Gynecology, Faculty of Medicine, King Abdulaziz University, P.O. Box 80205, Jeddah 21589, Saudi ArabiaBiochemistry Department, King Abdulaziz University, P.O. Box 80218, Jeddah 21589, Saudi ArabiaPolycystic ovary syndrome (PCOS) is one of the most prevalent endocrine diseases affecting women of reproductive age. The pathogeny of PCOS is still not completely understood, but one contributing factor that has been proposed is anti-Müllerian hormone (AMH). There is currently no clear correlation between levels of AMH and incidence of PCOS in Saudi Arabian patients. The goal of this study was to determine the threshold of AMH and correlate it with PCOS clinical features to facilitate a proper diagnosis for PCOS. In this case-control study, we recruited 79 PCOS women and 69 normal ovulatory women; PCOS patients were diagnosed according to the Rotterdam criterion. On days 2−4 of the menstrual cycle, transvaginal/abdominal ultrasound was performed and serum levels of AMH, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) were measured for all participants. The receiver operating characteristic curve (ROC) was used to determine the AMH diagnostic cut-off at 3.19 ng/mL, with 72% sensitivity and 70% specificity; AMH > 3.19 ng/mL was significantly correlated with PCOS. High AMH levels were correlated with age at menarche, polycystic ovarian morphology (PCOM), and oligo/amenorrhea. Serum AMH is a promising diagnostic marker of ovarian dysfunction in PCOS patients especially in cases in which the evaluation of PCOM was complicated.https://www.mdpi.com/2075-4418/9/4/136polycystic ovary syndromeanti-müllerian hormoneoligo/amenorrheahyperandrogenism |
| spellingShingle | Nada Ahmed Asma A. Batarfi Osama S. Bajouh Sherin Bakhashab Serum Anti-Müllerian Hormone in the Diagnosis of Polycystic Ovary Syndrome in Association with Clinical Symptoms Diagnostics polycystic ovary syndrome anti-müllerian hormone oligo/amenorrhea hyperandrogenism |
| title | Serum Anti-Müllerian Hormone in the Diagnosis of Polycystic Ovary Syndrome in Association with Clinical Symptoms |
| title_full | Serum Anti-Müllerian Hormone in the Diagnosis of Polycystic Ovary Syndrome in Association with Clinical Symptoms |
| title_fullStr | Serum Anti-Müllerian Hormone in the Diagnosis of Polycystic Ovary Syndrome in Association with Clinical Symptoms |
| title_full_unstemmed | Serum Anti-Müllerian Hormone in the Diagnosis of Polycystic Ovary Syndrome in Association with Clinical Symptoms |
| title_short | Serum Anti-Müllerian Hormone in the Diagnosis of Polycystic Ovary Syndrome in Association with Clinical Symptoms |
| title_sort | serum anti mullerian hormone in the diagnosis of polycystic ovary syndrome in association with clinical symptoms |
| topic | polycystic ovary syndrome anti-müllerian hormone oligo/amenorrhea hyperandrogenism |
| url | https://www.mdpi.com/2075-4418/9/4/136 |
| work_keys_str_mv | AT nadaahmed serumantimullerianhormoneinthediagnosisofpolycysticovarysyndromeinassociationwithclinicalsymptoms AT asmaabatarfi serumantimullerianhormoneinthediagnosisofpolycysticovarysyndromeinassociationwithclinicalsymptoms AT osamasbajouh serumantimullerianhormoneinthediagnosisofpolycysticovarysyndromeinassociationwithclinicalsymptoms AT sherinbakhashab serumantimullerianhormoneinthediagnosisofpolycysticovarysyndromeinassociationwithclinicalsymptoms |